Back to search
Advanced HBV-Related Hepatocellular Carcinoma (HCC)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced HBV-Related Hepatocellular Carcinoma (HCC) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced HBV-Related Hepatocellular Carcinoma (HCC) trials you may qualify forThis early phase (Phase 1) study will evaluate BRII 5395, administered in combination with two approved anticancer agents, sintilimab and bevacizumab, in patien…
This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus…
The purpose of this study is to evaluate the efficacy and safety of mRNA vaccine for HBV-positive Advanced Hepatocellular Carcinoma.
Adoptive cell therapy with TCR-T cells targeting HBV antigens represents an innovative opportunity for treatment of HBV-related HCC. SCG101 is a genetically mod…
The enriched HBV-related advanced HCC patient population (composite biomarker score ≥ 2) and overall survival (OS) were compared between the two groups.
To evaluate the safety, tolerability and efficacy of autologous γδT cells in the treatment of advanced hepatitis B-related hepatocellular carcinoma.